Arcutis Biotherapeutics, Inc., formerly known as Arcutis, Inc., was established in June 2016 under the laws of the State of Delaware and later changed its name to Arcutis Biotherapeutics, Inc. The company is a late-stage biopharmaceutical company dedicated to the development and commercialization of treatments for skin diseases with unmet medical needs. The company's current product portfolio includes topical treatments with the potential to address immune-mediated skin diseases and diseases or immune skin diseases. The company's strategy is to identify and develop therapies against proven biological targets in dermatology to provide differentiated clinical features that address the major shortcomings of existing therapies in terms of target indications.